http://www.fpnotebook.com/
SaquinavirAka: Invirase
- Mechanism
- Disadvantages
- Weak effect
- Expensive
- May worsen resistance for better drugs
- Drug Interactions
- Garlic supplements (do not use with Saquinavir)
- Reduces Saquinavir concentrations by 50%
- Levels may remain reduced even after stopiing Garlic
- Piscitelli (2002) Clin Infect Dis 34:234
- Garlic supplements (do not use with Saquinavir)
- Dosing
- Saquinavir 600 mg PO tid ($572/month)
- If taken without food, may have no antiviral activity
- Take within 2 hours after a full meal
- Meals increase absorption and decrease GI upset
Saquinavir (C0286738) | |
|---|---|
| Definition (CSP) | HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. |
| Definition (MSH) | An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. |
| Definition (NCI) | A synthetic antiviral agent. Saquinavir, a peptide-like substrate, selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D019258 |
| English | Saquinavir, SAQUINAVIR PREPARATION, Saquinavir product, Saquinivir, SQV |
| Spanish | saquinavir |
| Parent Concepts | Antiviral Agents (C0003451), Protease Inhibitor (C0033607), Isoquinolines (C0022248), Quinolines (C0034424), Retroviral protease inhibitor (C1268897), Drug allergen (C1320237), HIV Protease Inhibitors (C0162714) |
| Sources | CSP, LNC, MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Invirase (C0701215) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D019258 |
| English | Invirase |
| Sources | CSP, MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
